Kane Biotech

Kane Biotech FCF/Debt

The Free Cash Flow to Debt Ratio of Kane Biotech (KNE.V) as of Oct 20, 2026 is -545.82 %. In the previous year, Free Cash Flow to Debt Ratio was -438.46 % — a change of 24.48% (lower).

FCF/Debt

-545.82 %

YoY

24.48%

Last updated:

Free Cash Flow to Debt Ratio of Kane Biotech is 2025 -545.82 % . Free Cash Flow to Debt Ratio of Kane Biotech was 2024 -438.46 % . It decreases by 24.48% lower compared to the previous year.

The Kane Biotech FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
-600.06 CAD
Jan 1, 2019
-619.94 CAD
Jan 1, 2020
-180.68 CAD
Jan 1, 2021
-56.05 CAD
Jan 1, 2022
-45.66 CAD
Jan 1, 2023
-23.14 CAD
Jan 1, 2024
-438.46 CAD
Jan 1, 2025
-545.82 CAD
The Kane Biotech FCF/Debt history
YEARFCF/DebtYoY
-545.82 %+24.48%
-438.46 %+1,794.47%
-23.14 %-49.31%
-45.66 %-18.53%
-56.05 %-68.98%
-180.68 %-70.86%
-619.94 %+3.31%
-600.06 %-117.70%
3,390.16 %-718.88%
-547.79 %+60.41%
-341.50 %+23.92%
-275.57 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kane Biotech Stock analysis

What does Kane Biotech do? Kane Biotech, Inc. generates revenue through its portfolio of biotechnology products designed to prevent and remove microbial biofilms. The company commercializes StrixNB, DispersinB, Aledex, bluestem, silkstem, goldstem, coactiv+, and DermaKB Biofilm, with specific focus on the Wound Care & Surgical division developing DispersinB for chronic wound care. The bluestem product line targets animal health markets with water additives, chews, spray, and dental wipes, while Coactiv+ and DispersinB Gel are in development for antimicrobial wound rinse and prosthetic joint infection applications. Additional products include Scalp Detoxifier, Shampoo, and Shampoo Bars for consumer use. Kane Biotech serves animal health markets through its bluestem product line, which includes water additives, chews, spray, and dental wipes. The Wound Care & Surgical division targets medical applications, focusing on DispersinB for chronic wounds and developing Coactiv+ for antimicrobial wound rinse and surgical hydrogel. Consumer products like Scalp Detoxifier, Shampoo, and Shampoo Bars cater to personal care segments. The company's development-stage products such as Coactiv+ antimicrobial surgical hydrogel and DispersinB Gel for prosthetic joint infection represent future revenue streams. The company's primary markets include animal health for bluestem products, medical applications for Wound Care & Surgical division, and consumer personal care for Scalp Detoxifier and Shampoo products. DispersinB is central to the medical division, while bluestem dominates the animal health segment. Development-stage products like Coactiv+ and DispersinB Gel are positioned to address unmet needs in wound care and prosthetic infections, expanding the company's market reach into specialized medical and consumer health segments. Kane Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kane Biotech stock

Free Cash Flow to Debt Ratio of Kane Biotech is -545.82 % in 2025.

Free Cash Flow to Debt Ratio of Kane Biotech changed from -438.46 % to -545.82 %, representing a 24.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Kane Biotech since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Kane Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Kane Biotech

All Key Metrics — Kane Biotech